OpGen Inc (NASDAQ:OPGN) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $1.18 and last traded at $1.19, with a volume of 37923 shares. The stock had previously closed at $1.22.
Several equities research analysts have issued reports on OPGN shares. ValuEngine raised shares of OpGen from a “hold” rating to a “buy” rating in a research note on Tuesday, July 10th. HC Wainwright set a $8.00 price target on shares of OpGen and gave the company a “buy” rating in a research report on Friday, August 3rd. Finally, Zacks Investment Research raised shares of OpGen from a “sell” rating to a “buy” rating and set a $2.25 price target on the stock in a research report on Wednesday, July 11th.
The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 0.19. The stock has a market cap of $7.70 million, a price-to-earnings ratio of -0.12 and a beta of 1.51.
A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC purchased a new stake in shares of OpGen Inc (NASDAQ:OPGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned about 0.99% of OpGen at the end of the most recent quarter. Hedge funds and other institutional investors own 11.36% of the company’s stock.
About OpGen (NASDAQ:OPGN)
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.